Showing results (241-250 of 929) with videos related to
Sort By:
Pageof 93
Investigative Ophthalmology & Visual Science|August 1, 1997
Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanomaD J Blom, G P Luyten, C Mooy, et al.European Journal of Clinical Investigation|December 3, 1999
Capillary permeability is increased in normo- and microalbuminuric type 1 diabetic patients: amelioration by ACE-inhibitionP H Oomen, J Jager, K Hoogenberg, et al.Cancer Letters|January 30, 1997
Decreased expression of HLA class I on ocular melanoma cells following in vitro photodynamic therapyD J Blom, H J Schuitmaker, I de Waard-Siebinga, et al.Investigative Ophthalmology & Visual Science|December 6, 2016
Induction of Chemokine Secretion and Monocyte Migration by Human Choroidal Melanocytes in Response to Proinflammatory CytokinesTina Jehs, Carsten Faber, Maja S Udsen, et al.Journal of Immunology (Baltimore, Md. : 1950)|December 4, 2012
Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanomaLong V Ly, Marjolein Sluijter, Sjoerd H van der Burg, et al.The International Journal of Biological Markers|January 1, 1991
The clinical status of immunoscintigraphy with monoclonal antibodies in ocular melanomaD F Schaling, M J Jager, M J van Kroonenburg, et al.Clinical Kidney Journal|August 26, 2024
Decoy receptors as biomarkers for exploring aetiology and designing new therapiesCarmine Zoccali, Giovanni Tripepi, Vianda Stel, et al.Medical Engineering & Physics|December 2, 2020
The MemoFlex II, a non-robotic approach to follow-the-leader motion of a snake-like instrument for surgery using four predetermined physical tracksP W J Henselmans, C Culmone, D J Jager, et al.Ocular Oncology and Pathology|September 5, 2017
Multiple Pigmented Conjunctival Lesions following Intravitreal Injections in a Patient with Uveal MelanomaNiels J Brouwer, Gregorius P M Luyten, Sjoerd G van Duinen, et al.Lancet (London, England)|May 27, 2016
Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practicesBruce M Robinson, Tadao Akizawa, Kitty J Jager, et al.Pageof 93